Parents
Sign in to add mentor| Matthew P. Scott | grad student | 2006 | Stanford | |
| (The role of sterols and insulin-like growth factor 2 in medulloblastoma tumorigenesis.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Villarreal OE, Xu Y, Tran H, et al. (2025) Adaptive Plasticity Tumor Cells Modulate MAPK-Targeting Therapy Response in Colorectal Cancer. Biorxiv : the Preprint Server For Biology |
| Corcoran RB, Do KT, Kim JE, et al. (2024) Phase 1/2 study of combined BCL-xL and MEK inhibition with navitoclax and trametinib in KRAS or NRAS mutant advanced solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Balasooriya ER, Wu Q, Ellis H, et al. (2024) The irreversible FGFR inhibitor KIN-3248 overcomes FGFR2 kinase domain mutations. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Rubinson DA, Tanaka N, Fece de la Cruz F, et al. (2024) Sotorasib is a pan-RASG12C inhibitor capable of driving clinical response in NRASG12C cancers. Cancer Discovery |
| Varkaris A, Fece de la Cruz F, Martin EE, et al. (2023) Allosteric PI3K-alpha inhibition overcomes on-target resistance to orthosteric inhibitors mediated by secondary PIK3CA mutations. Cancer Discovery |
| Tian J, Chen JH, Chao SX, et al. (2023) Combined PD-1, BRAF and MEK inhibition in BRAF colorectal cancer: a phase 2 trial. Nature Medicine |
| Sun Y, Revach OY, Anderson S, et al. (2023) Targeting TBK1 to overcome resistance to cancer immunotherapy. Nature |
| Cleary JM, Raghavan S, Wu Q, et al. (2021) FGFR2 Extracellular Domain In-Frame Deletions are Therapeutically Targetable Genomic Alterations that Function as Oncogenic Drivers in Cholangiocarcinoma. Cancer Discovery |
| Tanaka N, Lin JJ, Li C, et al. (2021) Clinical acquired resistance to KRASG12C inhibition through a novel KRAS switch-II pocket mutation and polyclonal alterations converging on RAS-MAPK reactivation. Cancer Discovery |
| Chaudhary S, Kwak EL, Hwang KL, et al. (2020) Revisiting MET: Clinical Characteristics and Treatment Outcomes of Patients with Locally Advanced or Metastatic, MET-Amplified Esophagogastric Cancers. The Oncologist |